
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Dr. Poulin discusses his poster which is a cost analysis of 300 patients from Quebec, Canada, in an atrial fibrillation and congestive heart failure trial.

